Are you interested in a new treatment for Alzheimer's disease?
Although the cause of Alzheimer’s disease is not yet clearly understood, it is believed that proteins in the brain, called beta-amyloid, are responsible. LY3202626 blocks a protein in the body called BACE1 that is responsible for the build-up of beta-amyloid. This study will look at whether the action of LY3202626 slows the progression of Alzheimer’s disease.
This study will look to answer the following research questions(s):
- The safety of LY3202626 and any side effects you might have when you take it.
- Whether LY3202626 can help patients with Alzheimer’s disease.
- How much LY3202626 should be given to patients.
Anticipated date that enrolment will close: December 2018
Who can take part
- People aged between 55 and 85 years
- Diagnosis of Alzheimer's Disease (MMSE 20-26)
- People living in the community
- Must have a study partner who is able to attend all visits with participant
What is involved for you
- Four visits in first month, then monthly visits for 1 year
- MRI and PET (x2) scans at beginning and end of study
- Numerous cognitive tests (beginning, middle and end of study)